Pharmaceutical Commerce

FEBRUARY 21, 2024

Cabenuva (cabotegravir + rilpivirine) showed superior efficacy in maintaining viral load suppression in patients with HIV compared with standard of care daily oral antiretroviral treatment.

111

111

Pharmafile

FEBRUARY 29, 2024

The drug is a first-in-class oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) for the […] The post AstraZeneca’s Voydeya recommended for approval in EU by CHMP appeared first on Pharmafile.

111

111

IDStewardship

APRIL 14, 2024

diff (oral vancomycin or fidaxomicin). Less than six months after the approval of Rebyota, the second FMT product (and first oral option) was FDA-approved. Her main areas of interest include critical care, emergency medicine, and infectious disease. Most cases of C. diff can then grow unchecked.

FDA 324

FDA Hospitals Communication 324

Drug Store News

AUGUST 3, 2023

After reviewing products projected to succeed from 2017 to 2022, the categories with the largest number of new items on shelves are first aid, pain relief, oral care and eye and ear care.

97

97

STAT

DECEMBER 19, 2022

Northern Maine and southern California don’t seem to have a lot in common — until you start looking for affordable, accessible dental care. In such disparate communities, and thousands in between, millions of Americans can’t access the dental care they need. Read the rest…

100

100

STAT

FEBRUARY 12, 2024

While staffing crises at hospitals continue to make headlines, dental care — too often overlooked and treated as separate from medical — is also experiencing a significant workforce challenge. That’s why regular dental care is so important. In my role leading dental at Sun Life U.S.,

Hospitals 105

Hospitals 105

pharmaphorum

DECEMBER 2, 2022

The initiative was originally funded by Health Resources and Service Administration and is now part of CareQuest’s grant-making efforts, aligned with its intentions for more accessible, equitable , and integrated oral health. Our [Oral Health] Champions can train their peers and create more advocates for oral health.”.

Medical Schools 52

Medical Schools 52

Pharmacy Times

SEPTEMBER 12, 2022

Deucravacitinib (Sotyktu) may become the new standard of care oral therapy for moderate-to-severe plaque psoriasis, according to investigators.

FDA 123

FDA 123

European Pharmaceutical Review

FEBRUARY 23, 2024

The interim data indicating the superiority of long-acting therapy compared to daily oral therapy in individuals who have difficulty taking pills for HIV every day is a remarkable outcome,” shared Dr Kimberly Smith, MPH, Head of R&D at ViiV Healthcare. ViiV Healthcare confirmed.

88

88

Pharma Mirror

DECEMBER 6, 2023

Oral health is a critical component of overall well-being, and growing research suggests that the health of your mouth is closely connected to your body’s overall health. The mouth serves as a gateway to the body, and any issues or infections that begin in the oral cavity can impact other systems and organs.

52

52

STAT

NOVEMBER 21, 2022

On Friday, oral health advocates across the globe got an early holiday gift from their longtime wish lists. They had been waiting their whole careers — for some STAT spoke with, up to nearly half a century — for oral health to be folded into conversations calling for health care access for all.

Hospitals 100

Hospitals 100

STAT

JANUARY 5, 2023

As 2023 begins, health care providers in the United States must make health records more easily available or risk losing Medicare funding under the 21st Century Cures Act. Read the rest…

103

103

European Pharmaceutical Review

APRIL 24, 2024

in clinical trials [the combination treatment was shown] to halt tumour growth for low-grade gliomas for an average of more than two years” The National Institute for Health and Care Excellence (NICE) has recommended a new targeted drug combination treatment for young people with BRAF V600E mutation-positive glioma.

Chemotherapy 64

Chemotherapy 64

Pharmafile

JANUARY 19, 2024

The drug is a first-in-class, oral, Factor D inhibitor, which has been developed as an add-on therapy to standard-of-care […] The post AstraZeneca’s Voydeya approved in Japan for PNH treatment appeared first on Pharmafile.

59

59

Pharmaceutical Technology

NOVEMBER 28, 2022

C4X Discovery (C4XD) and AstraZeneca have entered an exclusive global licensing agreement worth up to $402m to develop oral therapy to treat inflammatory and respiratory ailments. The deal has been signed to develop the C4X NRF2 Activator programme for these ailments. A key natural regulator, NRF2 controls antioxidant genes’ expression.

Immunization 105

Immunization 105

Pharmafile

NOVEMBER 30, 2023

Vivos Therapeutics has announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for the Vivos’ removable CARE (Complete Airway Repositioning and/or Expansion) oral appliances for the treatment of severe obstructive sleep apnea (OSA) in adult patients.

FDA 64

FDA 64

European Pharmaceutical Review

JUNE 1, 2023

An oral treatment for preventing migraines has been recommended by the National Institute for Health and Care Excellence (NICE) for the first time. How does the oral migraine treatment work? The post NICE recommends oral migraine treatment for first time appeared first on European Pharmaceutical Review.

78

78

STAT

SEPTEMBER 7, 2022

A new health care company was quietly incorporated last month, with plans to leverage cutting-edge inhalation technology and oral delivery expertise to treat everything from neurology to cardiovascular emergencies.

101

101

Pharma Mirror

JUNE 29, 2023

Dentistry, the art, and science of oral health, confines a diverse range of practices and professionals committed to maintaining the well-being of your teeth, gums, and overall oral health. appeared first on Pharma Mirror Magazine.

52

52

The Checkup by Singlecare

DECEMBER 6, 2023

According to Christine Franzese, MD , an allergist and immunologist at MU Health Care , sinus pressure is a symptom, not a disease or condition itself, so that it can be caused by any number of problems, including viral infections, allergies, bacterial infections, or even migraines. The most well-known of these nasal decongestants is Afrin.

FDA 105

FDA 105

Pharma Mirror

MARCH 17, 2024

Finding the right dentist in Whittier can be daunting, but it’s crucial for maintaining oral health. Real-life experiences can offer valuable insights into the quality of care a particular dentist provides. From routine check-ups to specialized treatments, a reliable dentist can make all the difference.

52

52

The Checkup by Singlecare

JULY 14, 2023

It’s the first time a nonprescription oral contraceptive will be available to consumers to prevent pregnancy. When used as directed, daily oral contraception is safe and is expected to be more effective than currently available nonprescription contraceptive methods in preventing unintended pregnancy,” she said. How does Opill work?

FDA 98

FDA Grocery Stores Packaging 98

The Checkup by Singlecare

NOVEMBER 16, 2023

According to the International Journal of Dentistry , tooth infections can occur as a result of cavities or tooth decay, trauma to the tooth, periodontal diseases, or poor oral hygiene, among other causes. For example, a typical course of oral amoxicillin is 500 mg , three times per day for three to seven days, according to the ADA.

Immunization 115

Immunization 115

STAT

NOVEMBER 1, 2022

Supreme Court heard oral arguments on Monday in two cases that could eliminate race as a factor in university’s admissions processes. Should the court overturn its earlier ruling, the implications would be felt broadly across all sectors of society — including the health care system. Read the rest…

Medical Schools 103

Medical Schools 103

European Pharmaceutical Review

FEBRUARY 22, 2024

The National Institute for Health and Care Excellence (NICE) has recommended LITFULO ® (ritlecitinib) for treating certain patients with severe alopecia areata. This is “an important milestone” according to Lynn Clay, Specialty Care Lead at Pfizer UK.

80

80

Hospital Pharmacy Europe

MARCH 26, 2024

The findings, published in the Journal of Infection , could improve care for individuals by giving patients a wider choice of antibiotics and easing the burden of antimicrobial resistance as more patients can safely be given penicillin. However, a large body of evidence suggests that 90-95% of PALs are inaccurate.

Labelling 52

Labelling Hospitals 52

European Pharmaceutical Review

JANUARY 19, 2023

The National Institute for Health and Care Excellence (NICE) has recommended Ninlaro ® (ixazomib) with lenalidomide and dexamethasone for treating relapsed/refractory multiple myeloma (RRMM). It was the first oral proteasome inhibitor to enter Phase III clinical trials and to receive a regulatory approval.

Hospitals 71

Hospitals Documentation 71

Pharmaceutical Technology

JULY 28, 2022

The use of long-acting injectable (LAI) formulations of these antipsychotics can help prevent hospitalisations related to symptom relapse, as these products are administered every fortnight or in one to six-month intervals, versus once or twice-daily oral antipsychotics. and 82.7%, respectively, of patients using oral aripiprazole.

98

98

European Pharmaceutical Review

SEPTEMBER 14, 2023

Rimegepant (Vydura) is the “first and only NICE-recommended medicine that can help alleviate the misery of acute migraines, and may be considered a step-change in treatment,” shared Helen Knight, Director of medicines evaluation at the National Institute for Health and Care Excellence (NICE).

97

97

The Checkup by Singlecare

MARCH 6, 2024

Veterinarians use gabapentin to treat pets, specifically dogs, with intervertebral disk disease, seizures, anxiety, or arthritis pain, according to Ray Spragley, DVM, CVA, CCRT , the founder of Zen Dog Veterinary Care in New York. 100 mg, oral capsules 200 mg, oral capsules 21-30 lbs.

Dosage 52

Dosage Compounding Labelling 52

The Checkup by Singlecare

NOVEMBER 14, 2022

Food and Drug Administration (FDA) has assigned “currently in shortage” status to oral powder for suspension amoxicillin. The American Society of Health-Systems Pharmacists (ASHP) has also posted on its website a list of the various oral amoxicillin products that are currently in short supply. In fact, as of Oct. What is amoxicillin?

FDA 105

FDA Pharmaceutical Companies Pharmaceutical Companies 105

Hospital Pharmacy Europe

JANUARY 18, 2023

It is the only triplet therapy that is all oral, meaning patients have to spend less time in hospital receiving treatment. The post Pioneering oral treatment for myeloma receives green light from NICE appeared first on Hospital Pharmacy Europe.

Hospitals 98

Hospitals 98

Pharmaceutical Technology

JUNE 14, 2023

Inobrodib is an oral first-in-class cancer drug, indicated for patients who have previously received four or more lines of therapy, including an anti-CD38 monoclonal antibody, an immunomodulatory agent and a proteasome inhibitor.

FDA 97

FDA 97

European Pharmaceutical Review

OCTOBER 20, 2022

Gedeon Richter has announced that its combined oral contraceptive Drovelis® is the first tablet containing estetrol (E4) and drospirenone (DRSP) to be made available on the NHS in England. The current known safety profile for the new drug combination is corroborative with the safety data for combined oral contraceptives.

79

79

pharmaphorum

JUNE 30, 2022

The FDA’s decision not to approve Spero Therapeutics’ oral antibiotic tebipenem Hbr for adults with complicated urinary tract infections (cUTI) further increases the threat of antibiotic resistance, according to a GlobalData analyst.

FDA 118

FDA Hospitals 118

European Pharmaceutical Review

JUNE 27, 2022

TPD is poised to be successful in delivering marketed products, but limitations are now starting to emerge, including tumour resistance, a lack of mechanisms for oral dosing, and the inability to penetrate tissues such as the CNS. Targeted protein degradation (TPD) therapy has grown rapidly as a field, with transformational potential.

88

88

Hospital Pharmacy Europe

JANUARY 5, 2023

Moreover, other anti-viral agents such as oral molnupiravir and nirmatrelvir plus ritonavir have all been shown to be effective at reducing COVID-19 disease progression. Consequently, in the present study, researchers conducted an open-label, randomised, phase 3 controlled study of favipiravir plus standard care versus standard care alone.

Labelling 52

Labelling Hospitals 52